Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
P 4 (1)

Trial Status

Recruiting2
Withdrawn1
Unknown1

Clinical Trials (4)

Showing 4 of 4 trials
NCT06331806Not ApplicableRecruitingPrimary

Myocardial Fibrosis Identification in Patients With Anthracycline-induced Cardiotoxicity

NCT06309862Recruiting

Immune Checkpoint Inhibitor Therapy for Cancer and Risk of Myocarditis or Cardiomyopathy

NCT03392740Phase 4WithdrawnPrimary

Prophylactic Lisinopril to Prevent Anthracycline Cardiomyopathy.

NCT04547465UnknownPrimary

2D Speckle-tracking Echocardiography in Chemotherapy-induced Cardiomyopathy With Cardiovascular Risk Factors

Showing all 4 trials

Research Network

Activity Timeline